Home LiteratureArticle Details
PMID: 26570998 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Pharmacogenomic agreement between two cancer cell line data sets.

Nature ·Vol. 528 ·No. 7580 ·2015-12-03 ·Pages 84-7

Cancer Cell Line Encyclopedia Consortium, Genomics of Drug Sensitivity in Cancer Consortium

Abstract

Large cancer cell line collections broadly capture the genomic diversity of human cancers and provide valuable insight into anti-cancer drug response. Here we show substantial agreement and biological consilience between drug sensitivity measurements and their associated genomic predictors from two publicly available large-scale pharmacogenomics resources: The Cancer Cell Line Encyclopedia and the Genomics of Drug Sensitivity in Cancer databases.

MeSH Terms
Cell Line, Tumor/drug effects Databases, Factual Datasets as Topic Humans Inhibitory Concentration 50 Neoplasms/drug therapy,genetics,pathology Pharmacogenetics Reproducibility of Results
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Cancer Cell Line Encyclopedia Consortium
Genomics of Drug Sensitivity in Cancer Consortium
Investigators
28 investigators, click to expand
Stransky Nicolas
Ghandi Mahmoud
Kryukov Gregory V
Garraway Levi A
Lehár Joseph
Liu Manway
Sonkin Dmitriy
Kauffmann Audrey
Venkatesan Kavitha
Edelman Elena J
Riester Markus
Barretina Jordi
Caponigro Giordano
Schlegel Robert
Sellers William R
Stegmeier Frank
Morrissey Michael
Amzallag Arnaud
Pruteanu-Malinici Iulian
Haber Daniel A
Ramaswamy Sridhar
Benes Cyril H
Menden Michael P
Iorio Francesco
Stratton Michael R
McDermott Ultan
Garnett Mathew J
Saez-Rodriguez Julio
References (10)
10 references, click to expand
  1. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
    Nature. 2005 Jul 7;436(7047):117-22 PMID: 16001072
  2. BRAF mutation predicts sensitivity to MEK inhibition.
    Nature. 2006 Jan 19;439(7074):358-62 PMID: 16273091
  3. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
    Cancer Cell. 2006 Dec;10(6):515-27 PMID: 17157791
  4. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
    J Clin Invest. 2009 Jun;119(6):1727-40 PMID: 19451690
  5. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.
    Nat Rev Cancer. 2010 Apr;10(4):241-53 PMID: 20300105
  6. Advances in the preclinical testing of cancer therapeutic hypotheses.
    Nat Rev Drug Discov. 2011 Mar;10(3):179-87 PMID: 21358737
  7. Systematic identification of genomic markers of drug sensitivity in cancer cells.
    Nature. 2012 Mar 28;483(7391):570-5 PMID: 22460902
  8. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
    Nature. 2012 Mar 28;483(7391):603-7 PMID: 22460905
  9. Comparison and validation of genomic predictors for anticancer drug sensitivity.
    J Am Med Inform Assoc. 2013 Jul-Aug;20(4):597-602 PMID: 23355484
  10. Inconsistency in large pharmacogenomic studies.
    Nature. 2013 Dec 19;504(7480):389-93 PMID: 24284626
Article Info
Journal
Nature
Abbr.
Nature
ISSN
1476-4687
Published
2015-12-03
Epub
2015-00-16
Pages
84-7
Language
English
Region
England
NLM ID
0410462
PMCID
PMC6343827
Subset
IM
Grants
Wellcome Trust · 102696 · United Kingdom
NHGRI NIH HHS · U54 HG006097 · United States
NHGRI NIH HHS · 1U54HG006097-01 · United States
Wellcome Trust · 102696STRATTON · United Kingdom
Wellcome Trust · 086357 · United Kingdom
Cancer Research UK · A16629 · United Kingdom
Wellcome Trust · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]